Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex

This article was originally published in The Pink Sheet Daily

Executive Summary

Driven by a desire to acquire Phase II nucleotide polymerase inhibitor INX-189, the pharma agrees to pay a 163% premium over Inhibitex’s closing share price on Jan. 6.


Related Content

Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge
Deals Of The Week Untangles The String Of Pearls
Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo
Does Bristol Nuc’s Possible Cardiac Toxicity Portend A Class Effect?
Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity
Biopharma Quarterly Deal Statistics, Q1 2012
GSK’s Bid For Human Genome Sciences: A Deal Decades In The Making
BMS Makes Deeper Dent In Asia Hepatitis Market As Baraclude Moves Toward Blockbuster Status
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts